(Q36568732)

15 August 2017

1 reference

title

The potential of antidiabetic thiazolidinediones for anticancer therapy (English)

1 reference

15 August 2017

Elisabetta Ceni

3

0 references

Andrea Galli

object named as

Andrea Galli

1

0 references

Tommaso Mello

object named as

Tommaso Mello

2

0 references

author name string

Elisabetta Surrenti

4

1 reference

15 August 2017

Calogero Surrenti

5

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Investigational Drugs

15 August 2017

published in

1 reference

15 August 2017

volume

15

1 reference

15 August 2017

issue

9

1 reference

15 August 2017

page(s)

1039-1049

1 reference

PPARgamma-mediated insulin sensitization: the importance of fat versus muscle

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Thiazolidinediones: metabolic actions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

The effect of PPARgamma ligands on the adipose tissue in insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

An overview on biological mechanisms of PPARs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Interdomain communication regulating ligand binding by PPAR-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

PPAR gamma, 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Terminal differentiation of human breast cancer through PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Thiazolidinediones inhibit growth of gastrointestinal, biliary, and pancreatic adenocarcinoma cells through activation of the peroxisome proliferator-activated receptor gamma/retinoid X receptor alpha pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Up-regulation of p21 gene expression by peroxisome proliferator-activated receptor gamma in human lung carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Ciglitazone-induced cellular anti-proliferation increases p27kip1 protein levels through both increased transcriptional activity and inhibition of proteasome degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor gamma-dependent activation of p21 in Panc-28 pancreatic cancer cells involves Sp1 and Sp4 proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor gamma-independent ablation of cyclin D1 by thiazolidinediones and their derivatives in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Target genes of peroxisome proliferator-activated receptor gamma in colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Retinoid receptors in human lung cancer and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator activated receptor-gamma ligands induced cell growth inhibition and its influence on matrix metalloproteinase activity in human myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Decreased synthesis of matrix metalloproteinase-7 and adhesion to the extracellular matrix proteins of human colon cancer cells treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

PPAR gamma is required for placental, cardiac, and adipose tissue development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Oxidized LDL regulates vascular endothelial growth factor expression in human macrophages and endothelial cells through activation of peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor gamma for monocyte recruitment and endothelial regeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

PPAR gamma signaling exacerbates mammary gland tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

APC-dependent suppression of colon carcinogenesis by PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

A phase II trial with rosiglitazone in liposarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

The preventive anti-oxidant action of thiazolidinediones: a new therapeutic prospect in diabetes and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.15.9.1039

10.1517/13543784.15.9.1039

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference